Research Report on China's Nicorandil Market, 2022-2031

In China, the crude incidence rate of hypertension among residents over the age of 18 is close to 30%, and the most common hazard of hypertension is coronary heart disease. By the end of 2021, it is estimated that the number of patients with coronary heart disease in China exceeded 11 million, and that number keeps rising due to environmental pollution and poor lifestyle habits.
Clinically, WHO classifies coronary heart disease into five types: asymptomatic myocardial ischemia (occult coronary heart disease), angina pectoris, myocardial infarction, ischemic heart failure (ischemic heart disease), and sudden death.
Angina is a clinical syndrome caused by acute, temporary ischemia and hypoxia of the myocardium due to insufficient blood supply to the coronary arteries. Population-based studies show that the incidence of angina increases with age, with the prevalence increasing from 5%-7% in women aged 45-64 years to 10%-12% in women aged 65-84 years, and from 4%-7% in men aged 45-64 years to 12%-14% in men aged 65-84 years.
The rising number of patients with coronary heart disease in China has contributed to the growth of the related drug market.
Nicorandil is an anti-anginal drug that both relieves angina symptoms and improves the prognosis of coronary artery disease, with both nitrate-like effects and ATP-sensitive potassium channel-opening effects. It can both dilate large coronary arteries and diastole coronary microcirculatory resistance vessels, increasing coronary blood flow and myocardial oxygen supply while decreasing myocardial oxygen consumption, which effectively relieve angina pectoris. Several global medication guidelines have made high-level recommendations for Nicorandil.
Nicorandil was developed by Chugai with SIGMART as its trade name. Nicorandil tablets were launched in Japan in 1984 as an anti-anginal drug while the injection was put into clinical use for unstable angina in 1993 and acute heart failure in 2007. Nicorandil from Chugai entered the Chinese market in 2009, and generic drugs from local Chinese companies have been marketed since then. in 2017, Nicorandil became reimbursable under the Chinese medical insurance.
researcher's survey data show that from 2017 to 2021, the sales value of nicorandil in the Chinese market kept increasing year by year. Even in the face of COVID-19, the sales value still achieved growth in 2021, reaching CNY618 million (USD92.7 million), with a CAGR of 72.4% from 2017 to 2021. The dosage forms of nicorandil sold in China include tablets and injection, with the latter already occupying the major market share in terms of sales value.
researcher expects that from 2022 to 2031, the number of patients with coronary heart disease and angina will continue to rise in China, and the demand for nicorandil in the Chinese market will keep growing.

Topics Covered:
- The Impact of COVID-19 on China’s Nicorandil Market
- Development Environment of Nicorandil in China
- Sales Volume and value of Nicorandil in China
- Sales Volume and Value of Nicorandil in China by Region
- Major Nicorandil Manufacturers in China and Their Market Share
- Sales Price of Nicorandil in China
- Prospects of China’s Nicorandil Market, 2022-2031